<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617976</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MS 120/2020</org_study_id>
    <nct_id>NCT05617976</nct_id>
  </id_info>
  <brief_title>Nalbuphine as an Adjuvant to Levobupivacaine in Caudal Analgesia in Children</brief_title>
  <official_title>Nalbuphine as an Adjuvant to Levobupivacaine in Caudal Analgesia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caudal anesthesia is the single most important pediatric regional anesthetic technique and is&#xD;
      increasingly performed in pediatric regional anesthesia practices. It is preferred in order&#xD;
      to relieve intra-operative and postoperative pain in children of all age groups undergoing&#xD;
      pelvi-abdominal or lower limbs surgeries using levobupivacaine 0.25%.Various adjuvants have&#xD;
      been added to levobupivacaine to prolong postoperative caudal analgesia. Nalbuphine as many&#xD;
      opioids can be added in caudal analgesia. This prospective randomized double blind study was&#xD;
      done to compare the effects of plain levobupivacaine versus Levobupivacaine plus nalbuphine&#xD;
      single-shot for postoperative pain relief in children undergoing hypospadius repair surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2020</start_date>
  <completion_date type="Actual">September 20, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Postoperative analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Face legs activity cry consolablity score (FLACC) (0-10) Score: 0, no pain; 1-3, mild pain; 4-7, moderate pain; 8-10, severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of analgesia</measure>
    <time_frame>24hours</time_frame>
    <description>Time to first analgesia request (TFAR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesic consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>total dose of rescue analgesic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Caudal Anesthesia</condition>
  <arm_group>
    <arm_group_label>Group L (levobupivacaine only group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg plus one ml normal saline after induction of general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L+N(levobupivacaine plus nalbuphen group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Caudal block was done in this group using levobupivacaine 0.25% with the dose of 1 ml /kg and nalbuphine 0.1 mg /kg in one ml normal saline after induction of general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>caudal block</intervention_name>
    <description>caudal block</description>
    <arm_group_label>Group L (levobupivacaine only group)</arm_group_label>
    <arm_group_label>Group L+N(levobupivacaine plus nalbuphen group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I, II.&#xD;
&#xD;
          -  Age 1-3 years.&#xD;
&#xD;
          -  Patients scheduled for hypospadias repair surgeries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA III, IV.&#xD;
&#xD;
          -  Signs of infection at site of injection.&#xD;
&#xD;
          -  Known coagulopathy disorder.&#xD;
&#xD;
          -  Mental and / or developmental retardation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>February 23, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

